Carson Allaria Wealth Management, Ltd. Crispr Therapeutics Ag Transaction History
Carson Allaria Wealth Management, Ltd.
- $180 Million
- Q2 2025
A detailed history of Carson Allaria Wealth Management, Ltd. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Carson Allaria Wealth Management, Ltd. holds 277 shares of CRSP stock, worth $17,938. This represents 0.01% of its overall portfolio holdings.
Number of Shares
277
Previous 399
30.58%
Holding current value
$17,938
Previous $13,000
-0.0%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding CRSP
# of Institutions
480Shares Held
63.9MCall Options Held
2.16MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$658 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$393 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$246 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$180 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$164 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $5.05B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....